Squarepoint’s Palvella Therapeutics PVLA Stock Holding History

Squarepoint’s Portfolio PVLA Stock Details PVLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$791K	Sell	5,176 -7,891	-60%	-$958K	﹤0.01%	3086
2026 Q1	$1.63M	Buy	+13,067	New	+$1.36M	﹤0.01%	2360
2024 Q2	–	Sell	-1,823	Closed	-$26.7K	–	4761
2024 Q1	$26.7K	Buy	+1,823	New	+$25.4K	﹤0.01%	3911
2021 Q4	–	Sell	-445	Closed	-$184K	–	3593
2021 Q3	$184K	Sell	445 -1,175	-73%	-$409K	﹤0.01%	2526
2021 Q2	$496K	Buy	+1,620	New	+$355K	﹤0.01%	2134
2020 Q4	–	Sell	-218	Closed	-$36K	–	3320
2020 Q3	$36K	Buy	+218	New	+$49.6K	﹤0.01%	2395
2020 Q2	–	Sell	-1,022	Closed	-$186K	–	2565
2020 Q1	$186K	Buy	1,022 +462	+83%	+$116K	﹤0.01%	1499
2019 Q4	$162K	Buy	+560	New	+$155K	﹤0.01%	2268
2019 Q3	–	Sell	-135	Closed	-$51K	–	2728
2019 Q2	$51K	Buy	+135	New	+$40.3K	﹤0.01%	2280
2018 Q3	–	Sell	-354	Closed	-$143K	–	2268
2018 Q2	$143K	Buy	354 +126	+55%	+$60K	﹤0.01%	1596
2018 Q1	$124K	Sell	228 -438	-66%	-$271K	﹤0.01%	1556
2017 Q4	$402K	Buy	+666	New	+$310K	0.01%	1327

Other funds holding PVLA

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Squarepoint's PVLA Position: Q2 2026 in Review

Squarepoint reduced its Palvella Therapeutics (PVLA) stake by 60% in Q2 2026, selling an estimated $958K and leaving 5,176 shares worth $791K. The position accounts for ﹤0.01% of the portfolio, ranked #3086.

Squarepoint first reported a position in PVLA in Q4 2017 and has held it in 12 quarters since. The position peaked at $1.63M in Q1 2026. 197 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

Squarepoint held 5,176 shares of Palvella Therapeutics worth $791K as of Q2 2026.
Squarepoint sold 7,891 Palvella Therapeutics shares in Q2 2026, an estimated $958K.
Palvella Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #3086 holding.
Squarepoint first reported a position in Palvella Therapeutics in Q4 2017 and has held it in 12 quarters since.
Squarepoint's Palvella Therapeutics position peaked at $1.63M in Q1 2026.
197 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.